logo

Catalent Inc. (CTLT)



Trade CTLT now with
  Date
  Headline
8/27/2019 7:41:15 AM Catalent Q4 Net Earnings $71.1 Mln Or $0.44/Shr Vs $82.7 Mln Or $0.61/Shr Last Year
6/24/2019 7:41:29 AM Catalent Intends To Offer $500 Mln Of Senior Unsecured Notes Due 2027
6/19/2019 7:03:20 AM Catalent To Buy Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy
4/15/2019 7:06:00 AM Catalent To Purchase Paragon Bioservices For $1.2 Bln
2/5/2019 7:36:55 AM Catalent Q2 Revenue $623.0 Mln , Up 3% As-reported, Or 5% In Constant Currency
1/7/2019 7:06:30 AM Catalent Begins $200 Mln Capital Investment In Its Biologics Business
12/3/2018 3:02:33 AM Biohaven Pharma Reports Positive Topline Results From Phase 3 Clinical Trial Zydis ODT Formulation Of Rimegepant
11/6/2018 7:36:56 AM Catalent Q1 Net Loss $14.4 Mln Or $0.10/shr Vs. Net Income $3.8 Mln Or $0.03/shr Last Year
8/28/2018 7:34:07 AM Catalent Q4 Revenue $685.3 Mln, Up 11% As-reported, Or 9% In Constant Currency
8/14/2018 3:01:21 AM Catalent Completes Tender Offer For Juniper Pharmaceuticals
7/23/2018 4:08:12 PM Catalent Announces Public Offering Of Common Stock
7/3/2018 3:02:45 AM Catalent To Buy Juniper Pharma
7/3/2018 3:02:44 AM Juniper Pharma Signs Definitive Agreement To Be Acquired By Catalent For $11.50/Shr Cash
5/9/2018 3:03:47 AM Biohaven Initiates Expanded Access Program For Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets For Patients With ALS
5/1/2018 7:48:29 AM Catalent Q3 Revenue $627.9 Mln, Up 18% As-reported, Or 13% In Constant Currency
3/6/2018 3:01:28 AM Biohaven Enrolls First Patient In Phase 3 Trial To Evaluate Rimegepant Zydis ODT In Acute Treatment Of Migraine
  
 
>